Parkinson's disease (PD) is a common neurodegenerative disorder primarily characterized
by the death of dopaminergic neurons that project from the substantia nigra pars compacta …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Parkinson's disease prevalence is rapidly increasing in an aging global population. With this
increase comes exponentially rising social and economic costs, emphasizing the immediate …

One of the most common monogenic forms of Parkinson disease (PD) is caused by
mutations in the LRRK2 gene that encodes leucine-rich repeat kinase 2 (LRRK2). LRRK2 …

Multiple lines of evidence indicate that immune system dysfunction has a role in Parkinson
disease (PD); this evidence includes clinical and genetic associations between autoimmune …

Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic
Parkinson's disease (PD). However, strategies aimed at ameliorating mitochondrial …

Parkinson's disease (PD) is the second most common neurodegenerative disease. About
2% of the population above the age of 60 is affected by the disease. The pathological …

Parkinson's disease is a progressive neurodegenerative condition associated with the
deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …

Over a period of more than 50 years, the symptomatic treatment of the motor symptoms of
Parkinson disease (PD) has been optimized using pharmacotherapy, deep brain …